Biohaven Ltd. (NYSE: BHVN) Stock Competitors & Peer Comparison
See BHVN's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BHVN and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BHVN | $16.95 | +17.87% | 2.6B | -3.66 | -$4.64 | N/A |
| VRTX | $547.29 | -1.01% | 138.9B | 28.76 | $19.03 | N/A |
| REGN | $814.79 | -2.25% | 83.9B | 17.86 | $45.63 | +0.45% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $1,047.10 | +2.71% | 65.1B | 94.50 | $11.08 | N/A |
| MRNA | $149.66 | -5.77% | 59.4B | -18.36 | -$8.15 | N/A |
| RVMDW | $12.12 | +1.17% | 47.7B | -1.68 | -$7.21 | N/A |
| RVMD | $215.44 | +1.92% | 45.8B | -24.43 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $375.80 | -0.15% | 40.2B | 66.16 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
BHVN vs VRTX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, VRTX has a market cap of 138.9B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while VRTX trades at $547.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas VRTX's P/E ratio is 28.76. In terms of profitability, BHVN's ROE is -13.29%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, BHVN is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
BHVN vs REGN Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, REGN has a market cap of 83.9B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while REGN trades at $814.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas REGN's P/E ratio is 17.86. In terms of profitability, BHVN's ROE is -13.29%, compared to REGN's ROE of +0.14%. Regarding short-term risk, BHVN is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
BHVN vs VRNA Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas VRNA's P/E ratio is -102.80. In terms of profitability, BHVN's ROE is -13.29%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, BHVN is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
BHVN vs ARGX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, ARGX has a market cap of 65.1B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while ARGX trades at $1,047.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas ARGX's P/E ratio is 94.50. In terms of profitability, BHVN's ROE is -13.29%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, BHVN is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
BHVN vs MRNA Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, MRNA has a market cap of 59.4B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while MRNA trades at $149.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas MRNA's P/E ratio is -18.36. In terms of profitability, BHVN's ROE is -13.29%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, BHVN is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
BHVN vs RVMDW Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, RVMDW has a market cap of 47.7B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while RVMDW trades at $12.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas RVMDW's P/E ratio is -1.68. In terms of profitability, BHVN's ROE is -13.29%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, BHVN is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
BHVN vs RVMD Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, RVMD has a market cap of 45.8B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while RVMD trades at $215.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas RVMD's P/E ratio is -24.43. In terms of profitability, BHVN's ROE is -13.29%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, BHVN is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
BHVN vs SGEN Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas SGEN's P/E ratio is -57.19. In terms of profitability, BHVN's ROE is -13.29%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, BHVN is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
BHVN vs ONC Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, ONC has a market cap of 40.2B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while ONC trades at $375.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas ONC's P/E ratio is 66.16. In terms of profitability, BHVN's ROE is -13.29%, compared to ONC's ROE of +0.14%. Regarding short-term risk, BHVN is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
BHVN vs ALNY Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, ALNY has a market cap of 32B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while ALNY trades at $239.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas ALNY's P/E ratio is 43.06. In terms of profitability, BHVN's ROE is -13.29%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, BHVN is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check ALNY's competition here
BioNTech SE (NASDAQ: BNTX)
BHVN vs BNTX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, BNTX has a market cap of 28.3B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while BNTX trades at $112.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas BNTX's P/E ratio is -14.60. In terms of profitability, BHVN's ROE is -13.29%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, BHVN is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
BHVN vs INSM Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, INSM has a market cap of 27B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while INSM trades at $124.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas INSM's P/E ratio is -30.27. In terms of profitability, BHVN's ROE is -13.29%, compared to INSM's ROE of -1.11%. Regarding short-term risk, BHVN is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check INSM's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
BHVN vs ROIV Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, ROIV has a market cap of 26.5B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while ROIV trades at $36.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas ROIV's P/E ratio is -34.96. In terms of profitability, BHVN's ROE is -13.29%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, BHVN is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
BHVN vs INCY Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, INCY has a market cap of 26B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while INCY trades at $128.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas INCY's P/E ratio is 17.22. In terms of profitability, BHVN's ROE is -13.29%, compared to INCY's ROE of +0.30%. Regarding short-term risk, BHVN is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
BHVN vs UTHR Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, UTHR has a market cap of 21.9B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while UTHR trades at $516.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas UTHR's P/E ratio is 18.49. In terms of profitability, BHVN's ROE is -13.29%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, BHVN is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
BHVN vs GMAB Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, GMAB has a market cap of 20.7B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while GMAB trades at $33.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas GMAB's P/E ratio is 25.43. In terms of profitability, BHVN's ROE is -13.29%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, BHVN is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
BHVN vs BGNE Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas BGNE's P/E ratio is -22.55. In terms of profitability, BHVN's ROE is -13.29%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, BHVN is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
BHVN vs DNA-WT Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, BHVN's ROE is -13.29%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, BHVN is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check DNA-WT's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
BHVN vs NBIX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, NBIX has a market cap of 15.7B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while NBIX trades at $156.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas NBIX's P/E ratio is 22.63. In terms of profitability, BHVN's ROE is -13.29%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, BHVN is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
BHVN vs JAZZ Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, JAZZ has a market cap of 15.7B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while JAZZ trades at $249.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas JAZZ's P/E ratio is 9.29. In terms of profitability, BHVN's ROE is -13.29%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, BHVN is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
BHVN vs BBIO Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, BBIO has a market cap of 15.5B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while BBIO trades at $79.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas BBIO's P/E ratio is -21.22. In terms of profitability, BHVN's ROE is -13.29%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, BHVN is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
BHVN vs ASND Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, ASND has a market cap of 15.5B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while ASND trades at $250.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas ASND's P/E ratio is -103.41. In terms of profitability, BHVN's ROE is -13.29%, compared to ASND's ROE of +1.90%. Regarding short-term risk, BHVN is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
BHVN vs EXEL Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, EXEL has a market cap of 14.1B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while EXEL trades at $56.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas EXEL's P/E ratio is 16.03. In terms of profitability, BHVN's ROE is -13.29%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, BHVN is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check EXEL's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
BHVN vs HALO Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, HALO has a market cap of 12.7B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while HALO trades at $107.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas HALO's P/E ratio is 19.97. In terms of profitability, BHVN's ROE is -13.29%, compared to HALO's ROE of +1.81%. Regarding short-term risk, BHVN is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check HALO's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
BHVN vs BMRN Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, BMRN has a market cap of 12.7B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while BMRN trades at $65.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas BMRN's P/E ratio is 31.54. In terms of profitability, BHVN's ROE is -13.29%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, BHVN is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check BMRN's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
BHVN vs KRTX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas KRTX's P/E ratio is -28.09. In terms of profitability, BHVN's ROE is -13.29%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, BHVN is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
BHVN vs ARWR Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, ARWR has a market cap of 12.6B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while ARWR trades at $89.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas ARWR's P/E ratio is -39.61. In terms of profitability, BHVN's ROE is -13.29%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, BHVN is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check ARWR's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
BHVN vs MDGL Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, MDGL has a market cap of 12.5B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while MDGL trades at $538.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas MDGL's P/E ratio is -42.10. In terms of profitability, BHVN's ROE is -13.29%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, BHVN is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check MDGL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
BHVN vs SMMT Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, SMMT has a market cap of 11.4B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while SMMT trades at $14.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas SMMT's P/E ratio is -12.71. In terms of profitability, BHVN's ROE is -13.29%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, BHVN is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check SMMT's competition here
Bio-Techne Corporation (NASDAQ: TECH)
BHVN vs TECH Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while TECH trades at $72.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas TECH's P/E ratio is 37.31. In terms of profitability, BHVN's ROE is -13.29%, compared to TECH's ROE of +0.09%. Regarding short-term risk, BHVN is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
BHVN vs RNAM Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas RNAM's P/E ratio is -17.39. In terms of profitability, BHVN's ROE is -13.29%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, BHVN is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
BHVN vs AXSM Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, AXSM has a market cap of 10.7B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while AXSM trades at $207.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas AXSM's P/E ratio is -54.09. In terms of profitability, BHVN's ROE is -13.29%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, BHVN is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check AXSM's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
BHVN vs KRYS Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, KRYS has a market cap of 10.6B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while KRYS trades at $359.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas KRYS's P/E ratio is 45.08. In terms of profitability, BHVN's ROE is -13.29%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, BHVN is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check KRYS's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
BHVN vs IONS Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, IONS has a market cap of 10.5B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while IONS trades at $63.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas IONS's P/E ratio is -36.84. In terms of profitability, BHVN's ROE is -13.29%, compared to IONS's ROE of -1.11%. Regarding short-term risk, BHVN is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check IONS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
BHVN vs PRAX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, PRAX has a market cap of 10.5B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while PRAX trades at $377.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas PRAX's P/E ratio is -29.19. In terms of profitability, BHVN's ROE is -13.29%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, BHVN is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check PRAX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
BHVN vs KYMR Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, KYMR has a market cap of 10.3B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while KYMR trades at $125.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas KYMR's P/E ratio is -39.23. In terms of profitability, BHVN's ROE is -13.29%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, BHVN is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check KYMR's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
BHVN vs CYTK Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, CYTK has a market cap of 9.9B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while CYTK trades at $79.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas CYTK's P/E ratio is -10.97. In terms of profitability, BHVN's ROE is -13.29%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, BHVN is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check CYTK's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
BHVN vs PTGX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, PTGX has a market cap of 9.7B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while PTGX trades at $151.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas PTGX's P/E ratio is 147.09. In terms of profitability, BHVN's ROE is -13.29%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, BHVN is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check PTGX's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
BHVN vs RXDX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas RXDX's P/E ratio is -56.47. In terms of profitability, BHVN's ROE is -13.29%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, BHVN is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check RXDX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
BHVN vs NUVL Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas NUVL's P/E ratio is -21.79. In terms of profitability, BHVN's ROE is -13.29%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, BHVN is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check NUVL's competition here
Immunovant, Inc. (NASDAQ: IMVT)
BHVN vs IMVT Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, IMVT has a market cap of 9.1B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while IMVT trades at $43.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas IMVT's P/E ratio is -15.56. In terms of profitability, BHVN's ROE is -13.29%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, BHVN is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check IMVT's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
BHVN vs CRNX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while CRNX trades at $84.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas CRNX's P/E ratio is -16.83. In terms of profitability, BHVN's ROE is -13.29%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, BHVN is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check CRNX's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
BHVN vs PCVX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, PCVX has a market cap of 8.8B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while PCVX trades at $61.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas PCVX's P/E ratio is -8.01. In terms of profitability, BHVN's ROE is -13.29%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, BHVN is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check PCVX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
BHVN vs IMGN Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas IMGN's P/E ratio is -111.55. In terms of profitability, BHVN's ROE is -13.29%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, BHVN is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check IMGN's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
BHVN vs IBRX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, IBRX has a market cap of 8.6B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while IBRX trades at $8.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas IBRX's P/E ratio is -8.51. In terms of profitability, BHVN's ROE is -13.29%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, BHVN is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check IBRX's competition here
Abivax S.A. (NASDAQ: ABVX)
BHVN vs ABVX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, ABVX has a market cap of 8.6B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while ABVX trades at $116.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas ABVX's P/E ratio is -61.08. In terms of profitability, BHVN's ROE is -13.29%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, BHVN is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check ABVX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
BHVN vs TGTX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, TGTX has a market cap of 8.4B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while TGTX trades at $55.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas TGTX's P/E ratio is 19.94. In terms of profitability, BHVN's ROE is -13.29%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, BHVN is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check TGTX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
BHVN vs BPMC Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas BPMC's P/E ratio is -51.58. In terms of profitability, BHVN's ROE is -13.29%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, BHVN is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
BHVN vs APGE Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while APGE trades at $134.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas APGE's P/E ratio is -31.17. In terms of profitability, BHVN's ROE is -13.29%, compared to APGE's ROE of -0.30%. Regarding short-term risk, BHVN is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check APGE's competition here
Alkermes plc (NASDAQ: ALKS)
BHVN vs ALKS Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, ALKS has a market cap of 8.2B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while ALKS trades at $49.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas ALKS's P/E ratio is 51.75. In terms of profitability, BHVN's ROE is -13.29%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, BHVN is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check ALKS's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
BHVN vs CERE Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas CERE's P/E ratio is -16.47. In terms of profitability, BHVN's ROE is -13.29%, compared to CERE's ROE of -0.72%. Regarding short-term risk, BHVN is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check CERE's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
BHVN vs SYRE Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, SYRE has a market cap of 8.1B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while SYRE trades at $93.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas SYRE's P/E ratio is -48.00. In terms of profitability, BHVN's ROE is -13.29%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, BHVN is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check SYRE's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
BHVN vs RYTM Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, RYTM has a market cap of 7.7B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while RYTM trades at $111.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas RYTM's P/E ratio is -35.97. In terms of profitability, BHVN's ROE is -13.29%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, BHVN is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check RYTM's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
BHVN vs CAI Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, CAI has a market cap of 7.6B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while CAI trades at $26.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas CAI's P/E ratio is 75.36. In terms of profitability, BHVN's ROE is -13.29%, compared to CAI's ROE of +0.19%. Regarding short-term risk, BHVN is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check CAI's competition here
Metsera, Inc. (NASDAQ: MTSR)
BHVN vs MTSR Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas MTSR's P/E ratio is -23.58. In terms of profitability, BHVN's ROE is -13.29%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, BHVN is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check MTSR's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
BHVN vs SRRK Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, SRRK has a market cap of 7.2B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while SRRK trades at $60.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas SRRK's P/E ratio is -17.40. In terms of profitability, BHVN's ROE is -13.29%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, BHVN is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check SRRK's competition here
CG Oncology Inc. (NASDAQ: CGON)
BHVN vs CGON Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, CGON has a market cap of 6.9B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while CGON trades at $78.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas CGON's P/E ratio is -29.15. In terms of profitability, BHVN's ROE is -13.29%, compared to CGON's ROE of -0.25%. Regarding short-term risk, BHVN is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check CGON's competition here
Merus N.V. (NASDAQ: MRUS)
BHVN vs MRUS Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas MRUS's P/E ratio is -17.05. In terms of profitability, BHVN's ROE is -13.29%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, BHVN is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
BHVN vs ACLX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas ACLX's P/E ratio is -28.27. In terms of profitability, BHVN's ROE is -13.29%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, BHVN is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check ACLX's competition here
Erasca, Inc. (NASDAQ: ERAS)
BHVN vs ERAS Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, ERAS has a market cap of 6.6B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while ERAS trades at $19.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas ERAS's P/E ratio is -20.59. In terms of profitability, BHVN's ROE is -13.29%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, BHVN is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check ERAS's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
BHVN vs RETA Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas RETA's P/E ratio is -66.29. In terms of profitability, BHVN's ROE is -13.29%, compared to RETA's ROE of +0.47%. Regarding short-term risk, BHVN is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check RETA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
BHVN vs BLTE Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, BLTE has a market cap of 6.3B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while BLTE trades at $156.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas BLTE's P/E ratio is -83.79. In terms of profitability, BHVN's ROE is -13.29%, compared to BLTE's ROE of -0.21%. Regarding short-term risk, BHVN is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check BLTE's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
BHVN vs COGT Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, COGT has a market cap of 6.3B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while COGT trades at $36.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas COGT's P/E ratio is -17.40. In terms of profitability, BHVN's ROE is -13.29%, compared to COGT's ROE of -0.73%. Regarding short-term risk, BHVN is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check COGT's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
BHVN vs CNTA Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas CNTA's P/E ratio is -22.63. In terms of profitability, BHVN's ROE is -13.29%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, BHVN is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check CNTA's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
BHVN vs TVTX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, TVTX has a market cap of 6.2B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while TVTX trades at $67.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas TVTX's P/E ratio is -149.16. In terms of profitability, BHVN's ROE is -13.29%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, BHVN is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check TVTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
BHVN vs DNTH Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, DNTH has a market cap of 6.2B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while DNTH trades at $110.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas DNTH's P/E ratio is -26.69. In terms of profitability, BHVN's ROE is -13.29%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, BHVN is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check DNTH's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
BHVN vs XENE Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, XENE has a market cap of 6.2B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while XENE trades at $63.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas XENE's P/E ratio is -13.57. In terms of profitability, BHVN's ROE is -13.29%, compared to XENE's ROE of -0.44%. Regarding short-term risk, BHVN is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check XENE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
BHVN vs PTCT Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while PTCT trades at $72.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas PTCT's P/E ratio is -31.20. In terms of profitability, BHVN's ROE is -13.29%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, BHVN is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check PTCT's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
BHVN vs MIRM Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, MIRM has a market cap of 6B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while MIRM trades at $98.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas MIRM's P/E ratio is -6.77. In terms of profitability, BHVN's ROE is -13.29%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, BHVN is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check MIRM's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
BHVN vs ORKA Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, ORKA has a market cap of 6B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while ORKA trades at $99.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas ORKA's P/E ratio is -51.26. In terms of profitability, BHVN's ROE is -13.29%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, BHVN is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check ORKA's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
BHVN vs DFTX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, DFTX has a market cap of 5.8B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while DFTX trades at $43.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas DFTX's P/E ratio is N/A. In terms of profitability, BHVN's ROE is -13.29%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, BHVN is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check DFTX's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
BHVN vs LGND Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while LGND trades at $287.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas LGND's P/E ratio is 31.60. In terms of profitability, BHVN's ROE is -13.29%, compared to LGND's ROE of +0.20%. Regarding short-term risk, BHVN is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check LGND's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
BHVN vs CRSP Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, CRSP has a market cap of 5.7B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while CRSP trades at $59.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas CRSP's P/E ratio is -12.44. In terms of profitability, BHVN's ROE is -13.29%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, BHVN is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check CRSP's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
BHVN vs CDTX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas CDTX's P/E ratio is -19.77. In terms of profitability, BHVN's ROE is -13.29%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, BHVN is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
BHVN vs ABCM Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, BHVN's ROE is -13.29%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, BHVN is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
BHVN vs ISEE Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas ISEE's P/E ratio is -22.44. In terms of profitability, BHVN's ROE is -13.29%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, BHVN is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
BHVN vs APLS Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas APLS's P/E ratio is 38.35. In terms of profitability, BHVN's ROE is -13.29%, compared to APLS's ROE of +0.40%. Regarding short-term risk, BHVN is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check APLS's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
BHVN vs ACAD Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, ACAD has a market cap of 5.1B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while ACAD trades at $29.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas ACAD's P/E ratio is 13.32. In terms of profitability, BHVN's ROE is -13.29%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, BHVN is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check ACAD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
BHVN vs DYN Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, DYN has a market cap of 4.9B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while DYN trades at $26.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas DYN's P/E ratio is -8.19. In terms of profitability, BHVN's ROE is -13.29%, compared to DYN's ROE of -0.64%. Regarding short-term risk, BHVN is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check DYN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
BHVN vs EWTX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while EWTX trades at $44.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas EWTX's P/E ratio is -23.99. In terms of profitability, BHVN's ROE is -13.29%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, BHVN is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check EWTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
BHVN vs TERN Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas TERN's P/E ratio is -51.41. In terms of profitability, BHVN's ROE is -13.29%, compared to TERN's ROE of -0.20%. Regarding short-term risk, BHVN is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check TERN's competition here
Celcuity Inc. (NASDAQ: CELC)
BHVN vs CELC Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, CELC has a market cap of 4.6B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while CELC trades at $95.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas CELC's P/E ratio is -22.11. In terms of profitability, BHVN's ROE is -13.29%, compared to CELC's ROE of -3.51%. Regarding short-term risk, BHVN is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check CELC's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
BHVN vs PBLS Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, PBLS has a market cap of 4.6B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while PBLS trades at $39.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas PBLS's P/E ratio is -44.61. In terms of profitability, BHVN's ROE is -13.29%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, BHVN is more volatile compared to PBLS. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check PBLS's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
BHVN vs FOLD Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas FOLD's P/E ratio is -161.00. In terms of profitability, BHVN's ROE is -13.29%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, BHVN is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
BHVN vs AKRO Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas AKRO's P/E ratio is -14.57. In terms of profitability, BHVN's ROE is -13.29%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, BHVN is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
BHVN vs ALPN Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas ALPN's P/E ratio is -101.52. In terms of profitability, BHVN's ROE is -13.29%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, BHVN is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check ALPN's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
BHVN vs ELVN Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, ELVN has a market cap of 4.3B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while ELVN trades at $60.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas ELVN's P/E ratio is -36.45. In terms of profitability, BHVN's ROE is -13.29%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, BHVN is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check ELVN's competition here
Veradermics, Incorporated (NYSE: MANE)
BHVN vs MANE Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, MANE has a market cap of 4.3B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while MANE trades at $102.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas MANE's P/E ratio is -32.69. In terms of profitability, BHVN's ROE is -13.29%, compared to MANE's ROE of -0.29%. Regarding short-term risk, BHVN is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check MANE's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
BHVN vs RLAY Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, RLAY has a market cap of 4.3B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while RLAY trades at $19.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas RLAY's P/E ratio is -12.39. In terms of profitability, BHVN's ROE is -13.29%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, BHVN is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check RLAY's competition here
Opthea Limited (NASDAQ: OPT)
BHVN vs OPT Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas OPT's P/E ratio is -1.52. In terms of profitability, BHVN's ROE is -13.29%, compared to OPT's ROE of +1.18%. Regarding short-term risk, BHVN is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
BHVN vs PRTC Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas PRTC's P/E ratio is -3.78. In terms of profitability, BHVN's ROE is -13.29%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, BHVN is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check PRTC's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
BHVN vs ADPT Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, ADPT has a market cap of 4.2B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while ADPT trades at $26.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas ADPT's P/E ratio is -63.80. In terms of profitability, BHVN's ROE is -13.29%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, BHVN is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check ADPT's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
BHVN vs TNGX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, TNGX has a market cap of 4.1B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while TNGX trades at $25.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas TNGX's P/E ratio is -30.69. In terms of profitability, BHVN's ROE is -13.29%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, BHVN is more volatile compared to TNGX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check TNGX's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
BHVN vs AMLX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, AMLX has a market cap of 4.1B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while AMLX trades at $37.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas AMLX's P/E ratio is -24.72. In terms of profitability, BHVN's ROE is -13.29%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, BHVN is more volatile compared to AMLX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check AMLX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
BHVN vs MRTX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas MRTX's P/E ratio is -4.82. In terms of profitability, BHVN's ROE is -13.29%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, BHVN is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check MRTX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
BHVN vs VKTX Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while VKTX trades at $34.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas VKTX's P/E ratio is -7.38. In terms of profitability, BHVN's ROE is -13.29%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, BHVN is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check VKTX's competition here
IDEAYA Biosciences, Inc. (NASDAQ: IDYA)
BHVN vs IDYA Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, IDYA has a market cap of 4B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while IDYA trades at $41.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas IDYA's P/E ratio is -21.43. In terms of profitability, BHVN's ROE is -13.29%, compared to IDYA's ROE of -0.16%. Regarding short-term risk, BHVN is more volatile compared to IDYA. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check IDYA's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
BHVN vs DNLI Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, DNLI has a market cap of 3.9B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while DNLI trades at $24.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas DNLI's P/E ratio is -8.53. In terms of profitability, BHVN's ROE is -13.29%, compared to DNLI's ROE of -0.55%. Regarding short-term risk, BHVN is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check DNLI's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
BHVN vs RCUS Comparison August 2026
Biohaven Ltd. (NYSE: BHVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BHVN stands at 2.6B. In comparison, RCUS has a market cap of 3.9B. Regarding current trading prices, BHVN is priced at $16.95 on the NYSE, while RCUS trades at $30.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BHVN currently has a P/E ratio of -3.66, whereas RCUS's P/E ratio is -7.89. In terms of profitability, BHVN's ROE is -13.29%, compared to RCUS's ROE of -0.88%. Regarding short-term risk, BHVN is more volatile compared to RCUS. This indicates higher risk in terms of short-term price fluctuations for BHVN.Check RCUS's competition here